vs
MAXCYTE, INC.（MXCT）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是MAXCYTE, INC.的1.9倍（$9.1M vs $4.8M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -200.5%，领先140.1%），MAXCYTE, INC.同比增速更快（-20.9% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-2.9M），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -7.4%）
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
MXCT vs PLX — 直观对比
营收规模更大
PLX
是对方的1.9倍
$4.8M
营收增速更快
MXCT
高出29.0%
-49.9%
净利率更高
PLX
高出140.1%
-200.5%
自由现金流更多
PLX
多$4.5M
$-2.9M
两年增速更快
PLX
近两年复合增速
-7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $9.1M |
| 净利润 | $-9.6M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -234.5% | -51.1% |
| 净利率 | -200.5% | -60.3% |
| 营收同比 | -20.9% | -49.9% |
| 净利润同比 | 9.4% | -184.8% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MXCTPLX
| Q4 25 | $4.8M | $9.1M | ||
| Q3 25 | $4.6M | $17.9M | ||
| Q2 25 | $5.8M | $15.7M | ||
| Q1 25 | $5.7M | $10.1M | ||
| Q4 24 | $6.1M | $18.2M | ||
| Q3 24 | $5.6M | $18.0M | ||
| Q2 24 | $5.0M | $13.5M | ||
| Q1 24 | $5.6M | — |
净利润MXCTPLX
| Q4 25 | $-9.6M | $-5.5M | ||
| Q3 25 | $-12.4M | $2.4M | ||
| Q2 25 | $-12.4M | $164.0K | ||
| Q1 25 | $-10.3M | $-3.6M | ||
| Q4 24 | $-10.6M | $6.5M | ||
| Q3 24 | $-11.6M | $3.2M | ||
| Q2 24 | $-9.4M | $-2.2M | ||
| Q1 24 | $-9.5M | — |
毛利率MXCTPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率MXCTPLX
| Q4 25 | -234.5% | -51.1% | ||
| Q3 25 | -307.4% | 11.9% | ||
| Q2 25 | -244.3% | 7.5% | ||
| Q1 25 | -214.1% | -41.0% | ||
| Q4 24 | -213.1% | 39.6% | ||
| Q3 24 | -250.4% | 22.2% | ||
| Q2 24 | -241.0% | -18.0% | ||
| Q1 24 | -219.8% | — |
净利率MXCTPLX
| Q4 25 | -200.5% | -60.3% | ||
| Q3 25 | -269.7% | 13.2% | ||
| Q2 25 | -212.2% | 1.0% | ||
| Q1 25 | -178.7% | -35.8% | ||
| Q4 24 | -175.0% | 35.6% | ||
| Q3 24 | -205.9% | 18.0% | ||
| Q2 24 | -188.8% | -16.4% | ||
| Q1 24 | -170.6% | — |
每股收益（稀释后）MXCTPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.12 | $0.03 | ||
| Q2 25 | $-0.12 | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-0.11 | $0.03 | ||
| Q2 24 | $-0.09 | $-0.03 | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.0M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $171.5M | $48.2M |
| 总资产 | $202.5M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MXCTPLX
| Q4 25 | $103.0M | $14.7M | ||
| Q3 25 | $105.7M | $13.6M | ||
| Q2 25 | $126.6M | $17.9M | ||
| Q1 25 | $138.3M | $19.5M | ||
| Q4 24 | $154.5M | $19.8M | ||
| Q3 24 | $153.8M | $27.4M | ||
| Q2 24 | $157.3M | $23.4M | ||
| Q1 24 | $157.5M | — |
股东权益MXCTPLX
| Q4 25 | $171.5M | $48.2M | ||
| Q3 25 | $180.3M | $52.9M | ||
| Q2 25 | $190.7M | $49.9M | ||
| Q1 25 | $199.4M | $45.2M | ||
| Q4 24 | $206.3M | $43.2M | ||
| Q3 24 | $213.3M | $32.4M | ||
| Q2 24 | $221.3M | $28.6M | ||
| Q1 24 | $226.4M | — |
总资产MXCTPLX
| Q4 25 | $202.5M | $82.3M | ||
| Q3 25 | $213.5M | $82.3M | ||
| Q2 25 | $219.8M | $78.5M | ||
| Q1 25 | $230.0M | $73.9M | ||
| Q4 24 | $239.5M | $73.4M | ||
| Q3 24 | $248.6M | $61.6M | ||
| Q2 24 | $251.5M | $91.5M | ||
| Q1 24 | $257.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.7M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $1.6M |
| 自由现金流率自由现金流/营收 | -61.0% | 17.8% |
| 资本支出强度资本支出/营收 | 4.8% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流MXCTPLX
| Q4 25 | $-2.7M | $2.0M | ||
| Q3 25 | $-7.5M | $-3.7M | ||
| Q2 25 | $-9.9M | $-5.2M | ||
| Q1 25 | $-14.4M | $-5.1M | ||
| Q4 24 | $-7.8M | $4.0M | ||
| Q3 24 | $-4.4M | $4.1M | ||
| Q2 24 | $-4.8M | $-3.6M | ||
| Q1 24 | $-10.6M | — |
自由现金流MXCTPLX
| Q4 25 | $-2.9M | $1.6M | ||
| Q3 25 | $-7.8M | $-4.2M | ||
| Q2 25 | $-10.4M | $-5.7M | ||
| Q1 25 | $-15.1M | $-5.4M | ||
| Q4 24 | $-8.0M | $3.6M | ||
| Q3 24 | $-4.8M | $4.0M | ||
| Q2 24 | $-5.1M | $-3.8M | ||
| Q1 24 | $-11.4M | — |
自由现金流率MXCTPLX
| Q4 25 | -61.0% | 17.8% | ||
| Q3 25 | -168.5% | -23.7% | ||
| Q2 25 | -179.2% | -36.2% | ||
| Q1 25 | -262.3% | -53.0% | ||
| Q4 24 | -131.6% | 19.6% | ||
| Q3 24 | -85.5% | 22.4% | ||
| Q2 24 | -103.3% | -28.1% | ||
| Q1 24 | -203.6% | — |
资本支出强度MXCTPLX
| Q4 25 | 4.8% | 4.4% | ||
| Q3 25 | 6.5% | 2.8% | ||
| Q2 25 | 10.0% | 2.8% | ||
| Q1 25 | 11.4% | 3.0% | ||
| Q4 24 | 2.4% | 2.3% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 5.9% | 1.3% | ||
| Q1 24 | 14.4% | — |
现金转化率MXCTPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
